Case 2: Recommendations for Approaching Treatment of HR+ Breast Cancer
A panel of breast cancer experts share recommendations for adjuvant chemotherapy and endocrine therapy for a patient with HR-positive breast cancer and discuss approaches to toxicity management to increase adherence to therapy.
Watch
Case 2: SABCS 2021 Updates on SOFT and TEXT Trials for HR+ Breast Cancer
Joyce O’Shaughnessy, MD, leads a discussion on SABCS 2021 updates from the SOFT and TEXT trials for premenopausal women with HR-positive breast cancer.
Watch
Case 2: HR+ High-Risk Breast Cancer
Experts in breast cancer review the case of a 42-year-old woman with grade 2, node-positive invasive ductal carcinoma and discuss updated data from the RxPONDER trial on adjuvant chemotherapy benefit in premenopausal women.
Watch
Multifaceted Approach Used for Addressing Cardiotoxicity in Breast Cancer
March 5th 2022A team-oriented approach based on guideline-directed therapies should be used by clinicians to address patients experiencing cardiotoxicity as a result of their breast cancer, according Jean-Bernard Durand, MD.
Read More
Elacestrant Improves PFS Over SOC in Advanced ER-Positive, HER2-Negative Metastatic Breast Cancer
March 4th 2022Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.
Read More
Part 2: Managing Sacituzumab-Associated Neutropenia in TNBC
March 2nd 2022During a live virtual event, Sara Tolaney, MD, MPH, discussed the common issue of neutropenia in patients with triple-negative breast cancer who received sacituzumab govitecan in the ASCENT trial and in her clinical practice.
Read More
Case 1: Clinical Implications From MonarchE in HR+ Early Breast Cancer
Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, share insight on applying data presented from the monarchE study and the use of adjuvant abemaciclib in clinical practice for high-risk, HR+ early breast cancer.
Watch
Case 1: Role of Ki67 Testing in HR+ Early Breast Cancer
Sunil Badve, MD, FRCPath, and Heather McArthur, MD, evaluate best practices around Ki67 assessment when approaching treatment for HR+ early breast cancer.
Watch
Case 1: Using Adjuvant Abemaciclib for High-Risk HR+ Early Breast Cancer
Joyce O’ Shaughnessy, MD; Sunil Badve, MD, FRCPath; and Massimo Cristofanilli, MD, FACP, consider the role of adjuvant abemaciclib plus endocrine therapy for the treatment of patients with high-risk, node-positive, HR+ early breast cancer.
Watch
Case 1: MonarchE Study in High-Risk, HR+ Early Breast Cancer
Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’ Shaughnessy, MD, review the study design and clinical implications from the monarchE study for high-risk, HR+ early breast cancer.
Watch
Case 1: High-Risk, HR+/HER2- Early-Stage Breast Cancer
Experts in breast cancer review the case of a 54-year-old postmenopausal woman with stage IIB, high-risk, HR+ early-stage breast cancer and discuss factors to consider when assessing risk for systemic occurrence.
Watch
KEYNOTE-522 Shows Prolonged EFS With Adjuvant Pembrolizumab in High-Risk, Early-Stage TNBC
February 10th 2022In KEYNOTE-522, treatment with adjuvant pembrolizumab following neoadjuvant pembrolizumab with chemotherapy showed a statistically significant prolonged event-free survival in patients with high-risk early-stage triple-negative breast cancer.
Read More